Nanomedicine and Molecular Imaging Summit Offers an Event for Members of Science, Government, Medicine to Understand Nanotechnology in Order to Harness its Potential Albuquerque's blue skies and majestic mountains provided a scenic backdrop for a summit that explores one of the most promising technologies on the horizon - nanomedicine, or the medical application of molecular nanotechnology - a still-developing science dedicated to constructing microscopic probes and biomechanical devices. SNM's Nanomedicine and Molecular Imaging Summit, which began yesterday (February 1st) and continues today, brings together academic, government and industry experts from across a spectrum of disciplines to explore a topic that may have great application for diagnosing and treating disease in the future.
Invatec Comments On First Clinical Results Of Drug Eluting Balloon Technology For Below The Knee BtK
Invatec, a comprehensive innovator of interventional products, welcomed the first clinical results of the Drug Eluting Balloon (DEB), IN.PACT Amphirion, for complex Critical Limb Ischemia (CLI) in Below the Knee (BtK). As Dr. Andrej Schmidt, leading investigator from the Park Hospital Leipzig, reported during the LINC congress, preliminary results indicate a dramatic reduction in restenosis rate by application of the Drug Eluting Balloon. "In our experience, 69% of Clinical Limb Ischemia patients with long lesions show restenosis after 3 months. The Drug Eluting Balloon was able to bring this number down to 31%. Considering the mean lesion lengths of 17 cm and 58% rate of total occlusions prior to intervention, these results have the potential to change the way we treat complex CLI.
New advances for the detection of cancer led by Rafael V. Davalos of the Virginia Tech-Wake Forest School of Biomedical Engineering and Science (SBES) are featured as the cover story in the January 19, 2010 Royal Society of Chemistry's magazine, Lab on a Chip, the premier journal for researchers in microfluidics. Microfluidics is the behavior of fluids at the microscale level. A relatively new technology, it had already shown promise in revolutionizing certain procedures in molecular biology and in proteomics, among other fields. Building upon novel technology developed while working on Homeland Security projects at Sandia National Laboratories (SNL) as well as from his biomedical graduate student days at the University of California, Berkeley, Davalos, an assistant professor of biomedical engineering at Virginia Tech, is now creating unique microsystems that are showing considerable promise for the detection of cancer and for the study of the progression of this disease.
BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, is increasing the supply of its products available for donation in support of Haiti earthquake relief efforts from the $500, 000 announced on January 15 to $5 million in market value of critical medical supplies. This additional commitment will help BD's nonprofit partner organizations use and provide BD products they have specifically requested to address the healthcare disaster and ongoing needs in Haiti. BD regularly pre-positions product donations with AmeriCares, Catholic Medical Mission Board, Direct Relief International, Heart to Heart International and Project HOPE to enable these nonprofit organizations to respond swiftly in disaster situations around the world, such as the Haiti earthquake.
A University of Kentucky researcher is investigating respiratory weakness as a factor in the morbidity of intensive-care patients and will soon be testing new treatments that could improve long-term patient outcomes while reducing costs of care. Dr. Gerald Supinski, professor and vice chair of research for the Department of Internal Medicine in the University of Kentucky College of Medicine, was awarded a highly competitive, two-year, $480, 000/year NIH Challenge Grant for the project. Supinski suggests that patients who are exposed to prolonged mechanical ventilation in the intensive care unit (ICU) develop weakness in the skeletal muscles, which control breathing as well as body movement.
For quite some time, the "Holy Grail" in medical imaging has been the development of an effective method to image cell death as a means to intervene early in diseases and rapidly determine the effectiveness of treatments. A new paper by researchers at the University of Notre Dame and the Washington University School of Medicine describes important progress in using a synthetic probe to target dead and dying cells in mammary and prostate tumors in living animals. Bradley D. Smith, Emil T. Hofman Professor of Chemistry and Biochemistry at Notre Dame, points out that the group of researchers had previously discovered that synthetic zinc (II)-dipicolylamine (Zn-DPA) coordination complexes can selectively target the outer surfaces of anionic (negatively charged) cell membranes.